No. |
DrugBank |
Drug (Description in trials) [Number of descriptions] |
KEGG DRUG * | KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 | ARX201 | [1] Arx201; | - |
- |
- |
[1] 78 |
2 | Acetate | [76] 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate; | - |
- |
- |
[40] 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
3 | Acipimox | [1] Acipimox; | D07190 |
- |
- |
[2] 78, 265 |
4 | Amitriptyline | [3] Amitriptyline; Amitriptyline, fluoxetine and tramadol alone (control group); Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); | D00809 D07448 |
[2] SLC6A2, SLC6A4 |
[2] Serotonergic synapse, Synaptic vesicle cycle |
[3] 78, 226, 299 |
5 | Anastrozole | [2] Anastrozole; Arimidex (anastrozole); | D00960 |
[1] CYP19A1 |
[3] Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis |
[3] 78, 86, 193 |
6 | Caffeine | [5] Caffeine; Caffeine 100 mg; Caffeine 100-200 mg bid; Caffeine alkaloid; Dextromethorphan and caffeine; | D00528 D01453 |
[11] ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A |
[22] Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[6] 2, 6, 46, 78, 96, 97 |
7 | Camphor | - | D00098 D04761 D06392 D06620 |
- |
- |
[1] 78 |
8 | Clonidine | [3] Clonidine; Clonidine hcl cf 0,150 mg, tabletten; Clonidine hydrochloride; | D00281 D00604 |
[3] ADRA2A, ADRA2B, ADRA2C |
[2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
[2] 6, 78 |
9 | Corticorelin | - | D03905 |
[2] CRHR1, CRHR2 |
[3] Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction |
[2] 75, 78 |
10 | Corticotropin | [8] Corticotropin; Corticotropin releasing hormone; Corticotropin-releasing hormone; H.p. acthar gel (repository corticotropin injection); H.p. acthar® gel (repository corticotropin injection); Ovine corticotropin-releasing hormone (ocrh); Repository corticotropin injection; Repository corticotropin injection -treatment extension; | D00146 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[12] 2, 13, 46, 49, 50, 66, 75, 78, 84, 145, 193, 222 |
11 | Dextromethorphan | [9] Dextromethorphan; Dextromethorphan 30 mg; Dextromethorphan and caffeine; Dextromethorphan hbr and quinidine sulfate; Dextromethorphan hydrobromide; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg); Dimebon + dextromethorphan; | D00848 D03742 D03744 |
[5] GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
[17] Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
[9] 2, 6, 8, 13, 46, 78, 96, 97, 156 |
12 | Donepezil | [4] Donepezil; Donepezil hci (drug); Donepezil hydrochloride; Donepezil sandoz; | D00670 D07869 |
[1] ACHE |
[2] Cholinergic synapse, Glycerophospholipid metabolism |
[9] 5, 6, 13, 46, 78, 124, 127, 156, 206 |
13 | Fluoxetine | [4] Amitriptyline, fluoxetine and tramadol alone (control group); Fluoxetine; Fluoxetine hydrochloride; Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); | D00326 D00823 |
[1] SLC6A4 |
[2] Serotonergic synapse, Synaptic vesicle cycle |
[6] 13, 17, 78, 86, 179, 206 |
14 | Gelatin | [3] Bio-enhanced curcumin soft gelatin capsule; Gelatin; Neoral soft gelatin capsules; | D00115 D06892 |
- |
- |
[4] 47, 78, 97, 269 |
15 | Glucagon | [1] Glucagon; | D00116 D02118 |
[1] GCGR |
[2] Glucagon signaling pathway, Neuroactive ligand-receptor interaction |
[1] 78 |
16 | Human Serum Albumin | [4] Human serum albumin; Human serum albumin (hsa) fused to recombinant human growth hormone (hgh); Human serum albumin (hsa) fused to somatropin; Recombinant human serum albumin (hsa) fused to human growth hormone (hgh); | D05424 |
- |
- |
[3] 2, 78, 96 |
17 | Hydrocortisone | [22] Combination oral budesonide and rectal hydrocortisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortef (hydrocortisone); Dual release hydrocortisone (plenadren); Hydrocortisone; Hydrocortisone (solucortef); Hydrocortisone 10mg tablet; Hydrocortisone 20mg tablets; Hydrocortisone cream; Hydrocortisone cream 1%; Hydrocortisone cream 10mg/g fna fagron; Hydrocortisone efcortesol & solu-cortef; Hydrocortisone modified release capsules; Hydrocortisone roussel; Hydrocortisone sodium acetate; Hydrocortisone sodium phosphate; Hydrocortisone sodium succinate; Hydrocortisone takeda, tabletter; Mesalazine with hydrocortisone sodium succinate; Solu-cortef (hydrocortisone); Subcutaneous hydrocortisone; Subcutaneous hydrocortisone 10mg; | D00088 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[8] 6, 53, 75, 78, 81, 83, 97, 299 |
18 | Hydrocortisone acetate | - | D00165 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[8] 6, 53, 75, 78, 81, 83, 97, 299 |
19 | L-Arginine | [3] L-arginine; Ng-monomethyl-l-arginine; Ng-monomethyl-l-arginine (drug); | D02982 |
- |
- |
[5] 67, 78, 113, 251, 299 |
20 | Lenomorelin | - | - |
- |
- |
[3] 6, 78, 299 |
21 | Levomenthol | - | D00064 |
[2] TRPA1, TRPM8 |
[1] Inflammatory mediator regulation of TRP channels |
[1] 78 |
22 | Levothyroxine | [1] Levothyroxine; | D01010 D08125 |
[2] THRA, THRB |
[2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
[2] 49, 78 |
23 | Liothyronine | [3] Liothyronine; Liothyronine i 131; Liothyronine sodium; | D01011 D08128 |
[2] THRA, THRB |
[2] Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
[3] 13, 78, 212 |
24 | Macimorelin | [2] Macimorelin; Macimorelin acetate; | D10563 |
[1] GHSR |
[3] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[1] 78 |
25 | Mecasermin | [2] Mecasermin; Mecasermin [rdna origin] 10mg/ml solution; | D03297 D04870 |
[2] GHR, IGF1R |
[33] AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
[6] 65, 78, 96, 168, 265, 299 |
26 | Methyl salicylate 2-ethylbutyrate | - | - |
- |
- |
[1] 78 |
27 | Niacin | [5] Dose-establishing study 1 niacin 250mg; Dose-establishing study 1 niacin 500mg; Dose-establishing study 2 niacin 500mg; Niacin; Niacin first; | D00049 |
- |
- |
[4] 6, 78, 79, 265 |
28 | Pegvisomant | [1] Pegvisomant; | D05394 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
29 | Peppermint oil | - | D05432 |
- |
- |
[1] 78 |
30 | Phosphate ion | - | - |
- |
- |
[29] 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
31 | Pioglitazone | [6] Actos (pioglitazone); Pioglitazone; Pioglitazone 15 mg; Pioglitazone and tretinoin; Pioglitazone or metformin; Tretinoin and pioglitazone hcl; | D00945 D08378 |
[1] PPARG |
[9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
[17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
32 | Sodium chloride | [14] 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Physiological serum (sodium chloride); Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 6%; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution; | D02056 |
- |
- |
[19] 6, 11, 13, 14, 17, 34, 46, 51, 53, 67, 78, 86, 97, 168, 193, 227, 228, 288, 299 |
33 | Somapacitan | [1] Somapacitan; | D11194 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
34 | Somatorelin | [1] Somatorelin; | D08523 |
[1] GHRHR |
[2] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction |
[2] 13, 78 |
35 | Somatostatin | [2] Long-acting somatostatin; Somatostatin; | D07431 |
[5] SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 |
[4] Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[2] 67, 78 |
36 | Somatotropin | [2] Recombinant human somatotropin; Somatotropin; | D02691 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[18] 2, 3, 13, 19, 46, 74, 75, 78, 96, 113, 191, 193, 195, 236, 265, 274, 276, 299 |
37 | Somatrogon | [1] Somatrogon; | D10990 |
- |
- |
[1] 78 |
38 | Somavaratan | [2] Somavaratan; Somavaratan (vrs-317); | D11193 |
[1] GHR |
[5] Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
[1] 78 |
39 | Strontium ranelate | [1] Strontium ranelate; | D08468 |
- |
- |
[1] 78 |
40 | Tesamorelin | [2] Tesamorelin; Tesamorelin (egrifta); | D06655 D09015 |
[1] GHRHR |
[2] Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction |
[2] 78, 265 |
41 | Testosterone | [7] Nebido® testosterone undecanoate 1000 mg/4 ml solution for injection; Sustanon (testosterone); Testosterone; Testosterone enanthate; Testosterone plus somatropin; Testosterone undecanoate; Transdermal testosterone gel; | D00075 D00957 D00958 D00959 D06085 D06087 |
[1] AR |
[3] Oocyte meiosis, Pathways in cancer, Prostate cancer |
[7] 1, 2, 3, 13, 78, 113, 265 |
42 | Tetracosactide | [4] Tetracosactide; Tetracosactide acetate; Tetracosactide hexaacetate; Tetracosactide hexacetaat; | D00284 |
[1] MC2R |
[5] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
[5] 78, 83, 113, 145, 222 |
43 | Tramadol | [5] Amitriptyline, fluoxetine and tramadol alone (control group); Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); Tramadol; Tramadol /acetaminophen; Tramadol hydrochloride + acetaminophen; | D01355 D08623 |
[1] OPRM1 |
[3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
[5] 46, 70, 78, 226, 271 |
44 | Water | [13] 15 o water; 15-o labeled water; 5% glucose water solution; Dextrose, 5% in water; High water intake; Lactose in water; Pl 12185/0002 & pl 12185/0005(water for injection); Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; Water; Water for injection; Water for injections; Water for injections, ep; | D00001 |
- |
- |
[22] 2, 5, 6, 13, 17, 19, 28, 35, 46, 53, 57, 63, 65, 67, 78, 84, 97, 193, 226, 271, 278, 299 |